Get the Stockscreener App
5.23
1.88%
-0.10
After Hours:
5.20
-0.03
-0.57%
Capsovision Inc stock is traded at $5.23, with a volume of 17,170.
It is down -1.88% in the last 24 hours and up +8.73% over the past month.
CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.
See More
Previous Close:
$5.33
Open:
$5.27
24h Volume:
17,170
Relative Volume:
0.47
Market Cap:
$244.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.15%
1M Performance:
+8.73%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.0965
$5.27
1-Week Range:
$5.065
$5.50
52-Week Range:
$3.4341
$5.70
Capsovision Inc Stock (CV) Company Profile
Name
Capsovision Inc
Sector
Industry
Phone
(408) 370-4790
Address
18805 COX AVENUE SUITE 250, SARATOGA
Compare CV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
5.23 | 249.67M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Roth Capital | Buy |
| Jul-28-25 | Initiated | The Benchmark Company | Speculative Buy |
Capsovision Inc Stock (CV) Latest News
CapsoVision (NASDAQ: CV) to Host 1:1 Investor Meetings at Benchmark Discovery Conference - Stock Titan
CapsoVision, Inc.Common Stock (NQ: CV - FinancialContent
CapsoVision (CV) Price Target Increased by 20.00% to 6.12 - Nasdaq
CapsoVision CFO Kevin Lundquist Steps Down - MSN
David Michael Garcia Net Worth (2025) - GuruFocus
CapsoVision reports Q3 EPS (17c) vs ($2.79) last year - MSN
Benchmark reiterates Speculative Buy rating on CapsoVision stock at $5 By Investing.com - Investing.com Australia
Benchmark reiterates Speculative Buy rating on CapsoVision stock at $5 - Investing.com
CapsoVision Reports Revenue Growth and Strategic Advances - TipRanks
CapsoVision Q3 2025 Earnings Call Transcript - MarketBeat
CapsoVision, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
CapsoVision, Inc. (CV) Q3 FY2025 earnings call transcript - Yahoo Finance
[8-K] CapsoVision, Inc Reports Material Event | CV SEC FilingForm 8-K - Stock Titan
CapsoVision Reports Third Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Ex - GuruFocus
CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Expect - Yahoo Finance
CapsoVision CFO Lundquist steps down - MSN
CapsoVision Seeks FDA Breakthrough Status for CapsoCam - MSN
CapsoVision seeks FDA breakthrough status for pancreatic cancer tool By Investing.com - Investing.com Nigeria
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - The Manila Times
CapsoVision (NASDAQ: CV) files for FDA Breakthrough designation for pancreatic capsule - Stock Titan
CapsoVision (NASDAQ:CV) and Bioventus (NASDAQ:BVS) Financial Contrast - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
United States Smart Pills Market to hit US$ 619.10 Million by 2033 - openPR.com
CapsoVision appoints David Garcia as SVP of finance By Investing.com - Investing.com Australia
[Form 3] CapsoVision, Inc Initial Statement of Beneficial Ownership - Stock Titan
[Form 4] CapsoVision, Inc Insider Trading Activity - Stock Titan
Capsovision, Inc. Appoints David Garcia as Senior Vice President of Finance and Principal Accounting Officer, Effective November 3, 2025 - MarketScreener
CapsoVision Appoints David Garcia as Finance VP - TipRanks
CapsoVision appoints David Garcia as SVP of finance - Investing.com
CapsoVision Appoints David Garcia as Senior Vice President of Finance - The Manila Times
CapsoVision Appoints New Principal Financial Officer - TradingView
CapsoVision, Inc. Appoints David Garcia as Principal Financial Officer, Effective from November 3, 2025 - MarketScreener
CapsoVision (NASDAQ: CV) names David Garcia SVP of Finance; ex-Matterport FP&A VP - Stock Titan
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025 - The Manila Times
CapsoVision (NASDAQ: CV) sets earnings results for Nov. 13; call at 4:30 ET with webcast - Stock Titan
CapsoVision (NASDAQ:CV) & Bioventus (NASDAQ:BVS) Critical Review - Defense World
Weiss Ratings Reaffirms "Sell (E-)" Rating for CapsoVision (NASDAQ:CV) - MarketBeat
CapsoVision prices $27.5M IPO - MSN
Reviewing Bioventus (NASDAQ:BVS) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc. (NASDAQ:CV) Short Interest Update - MarketBeat
CapsoVision's (CV) Sell (E-) Rating Reiterated at Weiss Ratings - MarketBeat
Analyzing Vyome (NASDAQ:HIND) and CapsoVision (NASDAQ:CV) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Short Interest in CapsoVision, Inc. (NASDAQ:CV) Rises By 430.0% - MarketBeat
Capsovision Inc Stock (CV) Financials Data
There is no financial data for Capsovision Inc (CV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):